Cargando…

Alzheimer’s Disease: Epidemiology and Clinical Progression

Alzheimer’s disease (AD) is prevalent throughout the world and is the leading cause of dementia in older individuals (aged ≥ 65 years). To gain a deeper understanding of the recent literature on the epidemiology of AD and its progression, we conducted a review of the PubMed-indexed literature (2014–...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahami Monfared, Amir Abbas, Byrnes, Michael J., White, Leigh Ann, Zhang, Quanwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095793/
https://www.ncbi.nlm.nih.gov/pubmed/35286590
http://dx.doi.org/10.1007/s40120-022-00338-8
_version_ 1784705831578632192
author Tahami Monfared, Amir Abbas
Byrnes, Michael J.
White, Leigh Ann
Zhang, Quanwu
author_facet Tahami Monfared, Amir Abbas
Byrnes, Michael J.
White, Leigh Ann
Zhang, Quanwu
author_sort Tahami Monfared, Amir Abbas
collection PubMed
description Alzheimer’s disease (AD) is prevalent throughout the world and is the leading cause of dementia in older individuals (aged ≥ 65 years). To gain a deeper understanding of the recent literature on the epidemiology of AD and its progression, we conducted a review of the PubMed-indexed literature (2014–2021) in North America, Europe, and Asia. The worldwide toll of AD is evidenced by rising prevalence, incidence, and mortality due to AD—estimates which are low because of underdiagnosis of AD. Mild cognitive impairment (MCI) due to AD can ultimately progress to AD dementia; estimates of AD dementia etiology among patients with MCI range from 40% to 75% depending on the populations studied and whether the MCI diagnosis was made clinically or in combination with biomarkers. The risk of AD dementia increases with progression from normal cognition with no amyloid-beta (Aβ) accumulation to early neurodegeneration and subsequently to MCI. For patients with Aβ accumulation and neurodegeneration, lifetime risk of AD dementia has been estimated to be 41.9% among women and 33.6% among men. Data on progression from preclinical AD to MCI are sparse, but an analysis of progression across the three preclinical National Institute on Aging and Alzheimer’s Association (NIA-AA) stages suggests that NIA-AA stage 3 (subtle cognitive decline with AD biomarker positivity) could be useful in combination with other tools for treatment decision-making. Factors shown to increase risk include lower Mini-Mental State Examination (MMSE) score, higher Alzheimer’s Disease Assessment Scale (ADAS-cog) score, positive APOE4 status, white matter hyperintensities volume, entorhinal cortex atrophy, cerebrospinal fluid (CSF) total tau, CSF neurogranin levels, dependency in instrumental activities of daily living (IADL), and being female. Results suggest that use of biomarkers alongside neurocognitive tests will become an important part of clinical practice as new disease-modifying therapies are introduced.
format Online
Article
Text
id pubmed-9095793
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-90957932022-05-13 Alzheimer’s Disease: Epidemiology and Clinical Progression Tahami Monfared, Amir Abbas Byrnes, Michael J. White, Leigh Ann Zhang, Quanwu Neurol Ther Review Alzheimer’s disease (AD) is prevalent throughout the world and is the leading cause of dementia in older individuals (aged ≥ 65 years). To gain a deeper understanding of the recent literature on the epidemiology of AD and its progression, we conducted a review of the PubMed-indexed literature (2014–2021) in North America, Europe, and Asia. The worldwide toll of AD is evidenced by rising prevalence, incidence, and mortality due to AD—estimates which are low because of underdiagnosis of AD. Mild cognitive impairment (MCI) due to AD can ultimately progress to AD dementia; estimates of AD dementia etiology among patients with MCI range from 40% to 75% depending on the populations studied and whether the MCI diagnosis was made clinically or in combination with biomarkers. The risk of AD dementia increases with progression from normal cognition with no amyloid-beta (Aβ) accumulation to early neurodegeneration and subsequently to MCI. For patients with Aβ accumulation and neurodegeneration, lifetime risk of AD dementia has been estimated to be 41.9% among women and 33.6% among men. Data on progression from preclinical AD to MCI are sparse, but an analysis of progression across the three preclinical National Institute on Aging and Alzheimer’s Association (NIA-AA) stages suggests that NIA-AA stage 3 (subtle cognitive decline with AD biomarker positivity) could be useful in combination with other tools for treatment decision-making. Factors shown to increase risk include lower Mini-Mental State Examination (MMSE) score, higher Alzheimer’s Disease Assessment Scale (ADAS-cog) score, positive APOE4 status, white matter hyperintensities volume, entorhinal cortex atrophy, cerebrospinal fluid (CSF) total tau, CSF neurogranin levels, dependency in instrumental activities of daily living (IADL), and being female. Results suggest that use of biomarkers alongside neurocognitive tests will become an important part of clinical practice as new disease-modifying therapies are introduced. Springer Healthcare 2022-03-14 /pmc/articles/PMC9095793/ /pubmed/35286590 http://dx.doi.org/10.1007/s40120-022-00338-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Tahami Monfared, Amir Abbas
Byrnes, Michael J.
White, Leigh Ann
Zhang, Quanwu
Alzheimer’s Disease: Epidemiology and Clinical Progression
title Alzheimer’s Disease: Epidemiology and Clinical Progression
title_full Alzheimer’s Disease: Epidemiology and Clinical Progression
title_fullStr Alzheimer’s Disease: Epidemiology and Clinical Progression
title_full_unstemmed Alzheimer’s Disease: Epidemiology and Clinical Progression
title_short Alzheimer’s Disease: Epidemiology and Clinical Progression
title_sort alzheimer’s disease: epidemiology and clinical progression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095793/
https://www.ncbi.nlm.nih.gov/pubmed/35286590
http://dx.doi.org/10.1007/s40120-022-00338-8
work_keys_str_mv AT tahamimonfaredamirabbas alzheimersdiseaseepidemiologyandclinicalprogression
AT byrnesmichaelj alzheimersdiseaseepidemiologyandclinicalprogression
AT whiteleighann alzheimersdiseaseepidemiologyandclinicalprogression
AT zhangquanwu alzheimersdiseaseepidemiologyandclinicalprogression